|Bid||5.30 x 1400|
|Ask||5.45 x 1100|
|Day's Range||5.27 - 5.50|
|52 Week Range||3.90 - 7.45|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||86.13|
|Earnings Date||Nov 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.33|
Subscribe to Yahoo Finance Plus to view Fair Value for AMRXLearn more
BRIDGEWATER, N.J., October 27, 2021--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ("Amneal" or the "Company") today announced that it is launching dexamethasone, 4mg and 6 mg, following Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA).
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...